Подписаться
Matthew W. Johnson
Matthew W. Johnson
Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University
Подтвержден адрес электронной почты в домене jhu.edu - Главная страница
Название
Процитировано
Процитировано
Год
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
RR Griffiths, MW Johnson, MA Carducci, A Umbricht, WA Richards, ...
Journal of Psychopharmacology 30 (12), 1181-1197, 2016
22262016
Human hallucinogen research: guidelines for safety
MW Johnson, WA Richards, RR Griffiths
Journal of Psychopharmacology 22 (6), 603-620, 2008
12932008
Within‐subject comparison of real and hypothetical money rewards in delay discounting
MW Johnson, WK Bickel
Journal of the experimental analysis of behavior 77 (2), 129-146, 2002
12802002
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
RR Griffiths, WA Richards, MW Johnson, UD McCann, R Jesse
Journal of psychopharmacology 22 (6), 621-632, 2008
11762008
Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial
AK Davis, FS Barrett, DG May, MP Cosimano, ND Sepeda, MW Johnson, ...
JAMA psychiatry 78 (5), 481-489, 2021
11192021
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
MW Johnson, A Garcia-Romeu, MP Cosimano, RR Griffiths
Journal of Psychopharmacology 28 (11), 983-992, 2014
10812014
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
RR Griffiths, MW Johnson, WA Richards, BD Richards, U McCann, ...
Psychopharmacology 218, 649-665, 2011
10532011
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
KA MacLean, MW Johnson, RR Griffiths
Journal of Psychopharmacology 25 (11), 1453-1461, 2011
10282011
Delay discounting in current and never-before cigarette smokers: similarities and differences across commodity, sign, and magnitude.
F Baker, MW Johnson, WK Bickel
Journal of abnormal psychology 112 (3), 382, 2003
7862003
Long-term follow-up of psilocybin-facilitated smoking cessation
MW Johnson, A Garcia-Romeu, RR Griffiths
The American journal of drug and alcohol abuse 43 (1), 55-60, 2017
7082017
The behavioral economics of substance use disorders: reinforcement pathologies and their repair
WK Bickel, MW Johnson, MN Koffarnus, J MacKillop, JG Murphy
Annual review of clinical psychology 10, 641-677, 2014
6902014
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction
A Garcia-Romeu, R R Griffiths, M W Johnson
Current drug abuse reviews 7 (3), 157-164, 2014
5842014
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and …
RR Griffiths, MW Johnson, WA Richards, BD Richards, R Jesse, ...
Journal of Psychopharmacology 32 (1), 49-69, 2018
5602018
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
FS Barrett, MW Johnson, RR Griffiths
Journal of Psychopharmacology 29 (11), 1182-1190, 2015
5542015
An algorithm for identifying nonsystematic delay-discounting data.
MW Johnson, WK Bickel
Experimental and clinical psychopharmacology 16 (3), 264, 2008
5532008
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
TM Carbonaro, MP Bradstreet, FS Barrett, KA MacLean, R Jesse, ...
Journal of Psychopharmacology 30 (12), 1268-1278, 2016
5462016
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
MW Johnson, PS Hendricks, FS Barrett, RR Griffiths
Pharmacology & therapeutics 197, 83-102, 2019
5002019
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
PS Hendricks, CB Thorne, CB Clark, DW Coombs, MW Johnson
Journal of Psychopharmacology 29 (3), 280-288, 2015
4662015
Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin
KA MacLean, JMS Leoutsakos, MW Johnson, RR Griffiths
Journal for the scientific study of religion 51 (4), 721-737, 2012
4452012
Psychedelics as medicines: an emerging new paradigm
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics 101 (2), 209-219, 2017
3902017
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20